Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Ral-Arf6 crosstalk regulates Ral dependent exocyst trafficking and anchorage independent growth signalling.

Pawar A, Meier JA, Dasgupta A, Diwanji N, Deshpande N, Saxena K, Buwa N, Inchanalkar S, Schwartz MA, Balasubramanian N.

Cell Signal. 2016 Sep;28(9):1225-36. doi: 10.1016/j.cellsig.2016.05.023. Epub 2016 Jun 4.

2.

RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.

Fang B.

Acta Biochim Biophys Sin (Shanghai). 2016 Jan;48(1):27-38. doi: 10.1093/abbs/gmv090. Epub 2015 Sep 7. Review.

PMID:
26350096
3.

EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer.

Dunne PD, Dasgupta S, Blayney JK, McArt DG, Redmond KL, Weir JA, Bradley CA, Sasazuki T, Shirasawa S, Wang T, Srivastava S, Ong CW, Arthur K, Salto-Tellez M, Wilson RH, Johnston PG, Van Schaeybroeck S.

Clin Cancer Res. 2016 Jan 1;22(1):230-42. doi: 10.1158/1078-0432.CCR-15-0603. Epub 2015 Aug 17.

4.

Divergent roles of CAAX motif-signaled posttranslational modifications in the regulation and subcellular localization of Ral GTPases.

Gentry LR, Nishimura A, Cox AD, Martin TD, Tsygankov D, Nishida M, Elston TC, Der CJ.

J Biol Chem. 2015 Sep 11;290(37):22851-61. doi: 10.1074/jbc.M115.656710. Epub 2015 Jul 27.

5.

Effects of RAL signal transduction in KRAS- and BRAF-mutated cells and prognostic potential of the RAL signature in colorectal cancer.

Győrffy B, Stelniec-Klotz I, Sigler C, Kasack K, Redmer T, Qian Y, Schäfer R.

Oncotarget. 2015 May 30;6(15):13334-46.

6.

The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer.

Guin S, Theodorescu D.

Acta Pharmacol Sin. 2015 Mar;36(3):291-7. doi: 10.1038/aps.2014.129. Epub 2015 Jan 5. Review.

7.

κB-Ras proteins regulate both NF-κB-dependent inflammation and Ral-dependent proliferation.

Oeckinghaus A, Postler TS, Rao P, Schmitt H, Schmitt V, Grinberg-Bleyer Y, Kühn LI, Gruber CW, Lienhard GE, Ghosh S.

Cell Rep. 2014 Sep 25;8(6):1793-807. doi: 10.1016/j.celrep.2014.08.015. Epub 2014 Sep 15.

8.

Ral small GTPase signaling and oncogenesis: More than just 15minutes of fame.

Gentry LR, Martin TD, Reiner DJ, Der CJ.

Biochim Biophys Acta. 2014 Dec;1843(12):2976-2988. doi: 10.1016/j.bbamcr.2014.09.004. Epub 2014 Sep 16. Review.

9.

Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers.

Hata AN, Yeo A, Faber AC, Lifshits E, Chen Z, Cheng KA, Walton Z, Sarosiek KA, Letai A, Heist RS, Mino-Kenudson M, Wong KK, Engelman JA.

Cancer Res. 2014 Jun 1;74(11):3146-56. doi: 10.1158/0008-5472.CAN-13-3728. Epub 2014 Mar 27.

10.

A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) study.

Aparicio J, García-Mora C, Martín M, Petriz ML, Feliu J, Sánchez-Santos ME, Ayuso JR, Fuster D, Conill C, Maurel J.

PLoS One. 2014 Jan 9;9(1):e82209. doi: 10.1371/journal.pone.0082209. eCollection 2014.

11.

Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression.

Guin S, Ru Y, Wynes MW, Mishra R, Lu X, Owens C, Barn AE, Vasu VT, Hirsch FR, Kern JA, Theodorescu D.

J Thorac Oncol. 2013 Dec;8(12):1492-501. doi: 10.1097/JTO.0000000000000007.

12.

Response to MLN8237 in pancreatic cancer is not dependent on RalA phosphorylation.

Neel NF, Stratford JK, Shinde V, Ecsedy JA, Martin TD, Der CJ, Yeh JJ.

Mol Cancer Ther. 2014 Jan;13(1):122-33. doi: 10.1158/1535-7163.MCT-12-1232. Epub 2013 Nov 12.

13.

Ral GTPases in tumorigenesis: emerging from the shadows.

Kashatus DF.

Exp Cell Res. 2013 Sep 10;319(15):2337-42. doi: 10.1016/j.yexcr.2013.06.020. Epub 2013 Jul 2. Review.

14.

Dual effects of Ral-activated pathways on p27 localization and TGF-β signaling.

Tazat K, Harsat M, Goldshmid-Shagal A, Ehrlich M, Henis YI.

Mol Biol Cell. 2013 Jun;24(11):1812-24. doi: 10.1091/mbc.E13-01-0007. Epub 2013 Apr 10.

15.

BAY61-3606 affects the viability of colon cancer cells in a genotype-directed manner.

Lau KS, Zhang T, Kendall KR, Lauffenburger D, Gray NS, Haigis KM.

PLoS One. 2012;7(7):e41343. doi: 10.1371/journal.pone.0041343. Epub 2012 Jul 18.

16.

Differential involvement of RalA and RalB in colorectal cancer.

Martin TD, Der CJ.

Small GTPases. 2012 Apr-Jun;3(2):126-30. doi: 10.4161/sgtp.19571.

17.

RalA and RalB proteins are ubiquitinated GTPases, and ubiquitinated RalA increases lipid raft exposure at the plasma membrane.

Neyraud V, Aushev VN, Hatzoglou A, Meunier B, Cascone I, Camonis J.

J Biol Chem. 2012 Aug 24;287(35):29397-405. doi: 10.1074/jbc.M112.357764. Epub 2012 Jun 14.

18.

Breaking up is hard to do: RalA, mitochondrial fission and cancer.

Kashatus DF, Counter CM.

Small GTPases. 2011 Nov 1;2(6):329-333.

19.

Phosphorylation by protein kinase Cα regulates RalB small GTPase protein activation, subcellular localization, and effector utilization.

Martin TD, Mitin N, Cox AD, Yeh JJ, Der CJ.

J Biol Chem. 2012 Apr 27;287(18):14827-36. doi: 10.1074/jbc.M112.344986. Epub 2012 Mar 5.

20.

The RalB small GTPase mediates formation of invadopodia through a GTPase-activating protein-independent function of the RalBP1/RLIP76 effector.

Neel NF, Rossman KL, Martin TD, Hayes TK, Yeh JJ, Der CJ.

Mol Cell Biol. 2012 Apr;32(8):1374-86. doi: 10.1128/MCB.06291-11. Epub 2012 Feb 13.

Items per page

Supplemental Content

Write to the Help Desk